Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered significant bleeding events. Pharmaceutical businesses, including the makers of Xarelto, possess a duty to ensure that their drugs are reasonably protected for use - and failure to accomplish so may possibly be grounds for compensation. Our lawyers are working tough to obtain these hurt by the drug the compensation they're entitled to.
Although bleeding can be a common complication linked with anticoagulants, it has been alleged that Xarelto is much more harmful than standard blood thinners since no antidote exists to reverse its blood-thinning effects. This implies that, in the event of an emergency, patients could be at danger for irreversible bleeding issues, like life-threatening internal and gastrointestinal hemorrhaging.
In the event you or perhaps a loved a single suffered a significant bleeding event after taking Xarelto, you may have legal recourse. For a lot more data, make contact with us nowadays to possess your case reviewed, totally free of charge.
Compensation Possibilitiesxarelto for atrial fibrillation
-compensation-photoThe plaintiffs in these lawsuits are looking for compensation from Bayer and Janssen for past and future medical bills, lost wages, pain and suffering and, in circumstances of death, funeral expenses. Furthermore, they may be seeking punitive damages, that are typically awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike standard anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs in the lawsuits allege severe and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a safe anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited
clotting, and lack of effectiveness in preventing harmful clotting.
Visit this page for a lot more details on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.